{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T20:31:09Z","timestamp":1793392269552,"version":"4.5.0"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2023,11,18]],"date-time":"2023-11-18T00:00:00Z","timestamp":1700265600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,11,18]],"date-time":"2023-11-18T00:00:00Z","timestamp":1700265600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100007343","name":"Universit\u00e0 degli Studi di Brescia","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100007343","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr. Treat. Options in Oncol."],"published-print":{"date-parts":[[2023,12]]},"abstract":"<jats:title>Opinion statement<\/jats:title><jats:p>Genetic assessment is crucial to address the correct treatment for advanced medullary thyroid cancer (MTC). Multi tyrosine kinase inhibitors (mTKIs) cabozantinib and vandetanib are good first line options, even vandetanib prescription is currently limited to RET mutated patients. Selective RET inhibitors such as pralsetinib could be a preferred upfront treatment in case of RET mutated MTC presenting common or gatekeeper RET mutations (e.g. M918T; V804L\/M). Selpercatinib, otherwise, can be prescribed as the second line after disease progression to mTKIs. The best option for subsequent lines is to consider inclusion in clinical trials or alternatively other mTKIs such as sunitinib, sorafenib, lenvatinib, or pazopanib could be evaluated. New perspectives include next-generation RET inhibitors able to overcome resistance mechanisms responsible for disease progression to standard mTKIs and RET inhibitors, and immunotherapy for MTC presenting with high tumor mutational burden.<\/jats:p>","DOI":"10.1007\/s11864-023-01145-5","type":"journal-article","created":{"date-parts":[[2023,11,18]],"date-time":"2023-11-18T09:02:23Z","timestamp":1700298143000},"page":"1815-1832","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["The Evolving Treatment Landscape of Medullary Thyroid Cancer"],"prefix":"10.1007","volume":"24","author":[{"given":"Marta","family":"Lagan\u00e0","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Cremaschi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1619-1986","authenticated-orcid":false,"given":"Andrea","family":"Alberti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danica M.","family":"Vodopivec Kuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Cosentini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfredo","family":"Berruti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,11,18]]},"reference":[{"issue":"6","key":"1145_CR1","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1089\/thy.2014.0335","volume":"25","author":"SA Wells","year":"2015","unstructured":"Wells SA, Asa SL, Dralle H, Elisei R, Evans DB, Gagel RF, et al. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid. 2015;25(6):567\u2013610.","journal-title":"Thyroid"},{"issue":"1","key":"1145_CR2","doi-asserted-by":"publisher","first-page":"49","DOI":"10.3892\/ol.2010.223","volume":"2","author":"M Stamatakos","year":"2011","unstructured":"Stamatakos M, Paraskeva P, Stefanaki C, Katsaronis P, Lazaris A, Safioleas K, et al. Medullary thyroid carcinoma: the third most common thyroid cancer reviewed. Oncol Lett. 2011;2(1):49\u201353.","journal-title":"Oncol Lett"},{"issue":"7","key":"1145_CR3","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1016\/j.annonc.2022.04.009","volume":"33","author":"S Filetti","year":"2022","unstructured":"\u2022\u2022 Filetti S, Durante C, Hartl DM, Leboulleux S, Locati LD, Newbold K, et al. ESMO Clinical Practice Guideline update on the use of systemic therapy in advanced thyroid cancer. Ann Oncol. 2022;33(7):674\u201384. European Guidelines on MTC treatment","journal-title":"Ann Oncol"},{"issue":"6","key":"1145_CR4","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1089\/thy.2005.15.531","volume":"15","author":"MA Kouvaraki","year":"2005","unstructured":"Kouvaraki MA, Shapiro SE, Perrier ND, Cote GJ, Gagel RF, Hoff AO, et al. RET proto-oncogene: a review and update of genotype-phenotype correlations in hereditary medullary thyroid cancer and associated endocrine tumors. Thyroid. 2005;15(6):531\u201344.","journal-title":"Thyroid"},{"issue":"2","key":"1145_CR5","doi-asserted-by":"publisher","first-page":"E364","DOI":"10.1210\/jc.2012-2703","volume":"98","author":"N Agrawal","year":"2013","unstructured":"Agrawal N, Jiao Y, Sausen M, Leary R, Bettegowda C, Roberts NJ, et al. Exomic sequencing of medullary thyroid cancer reveals dominant and mutually exclusive oncogenic mutations in RET and RAS. J Clin Endocrinol Metab. 2013;98(2):E364\u20139.","journal-title":"J Clin Endocrinol Metab"},{"issue":"4\u20135","key":"1145_CR6","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/j.cytogfr.2005.05.010","volume":"16","author":"E Arighi","year":"2005","unstructured":"Arighi E, Borrello MG, Sariola H. RET tyrosine kinase signaling in development and cancer. Cytokine Growth Factor Rev. 2005;16(4\u20135):441\u201367.","journal-title":"Cytokine Growth Factor Rev"},{"key":"1145_CR7","doi-asserted-by":"publisher","first-page":"175883592211016","DOI":"10.1177\/17588359221101691","volume":"14","author":"DM Vodopivec","year":"2022","unstructured":"\u2022 Vodopivec DM, Hu MI. RET kinase inhibitors for. Ther Adv Med Oncol. 2022;14:17588359221101692. This paper gives an interesting overview on new RET-inhibitors which could be used in MTC treatment.","journal-title":"Ther Adv Med Oncol"},{"issue":"Suppl 1","key":"1145_CR8","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1016\/j.ijsu.2017.02.064","volume":"41","author":"G Accardo","year":"2017","unstructured":"Accardo G, Conzo G, Esposito D, Gambardella C, Mazzella M, Castaldo F, et al. Genetics of medullary thyroid cancer: an overview. Int J Surg. 2017;41(Suppl 1):S2\u20136.","journal-title":"Int J Surg"},{"issue":"4","key":"1145_CR9","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1038\/nrendo.2016.11","volume":"12","author":"C Romei","year":"2016","unstructured":"Romei C, Ciampi R, Elisei R. A comprehensive overview of the role of the RET proto-oncogene in thyroid carcinoma. Nat Rev Endocrinol. 2016;12(4):192\u2013202.","journal-title":"Nat Rev Endocrinol"},{"issue":"8","key":"1145_CR10","doi-asserted-by":"publisher","first-page":"925","DOI":"10.6004\/jnccn.2022.0040","volume":"20","author":"RI Haddad","year":"2022","unstructured":"\u2022\u2022 Haddad RI, Bischoff L, Ball D, Bernet V, Blomain E, Busaidy NL, et al. Thyroid carcinoma, version 2.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2022;20(8):925\u201351. American Guidelines on MTC treatment","journal-title":"J Natl Compr Canc Netw."},{"issue":"10","key":"1145_CR11","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.1007\/s00268-007-9185-1","volume":"31","author":"A Machens","year":"2007","unstructured":"Machens A, Hauptmann S, Dralle H. Increased risk of lymph node metastasis in multifocal hereditary and sporadic medullary thyroid cancer. World J Surg. 2007;31(10):1960\u20135.","journal-title":"World J Surg"},{"issue":"1\u20132","key":"1145_CR12","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.mce.2007.12.016","volume":"284","author":"S Dvorakova","year":"2008","unstructured":"Dvorakova S, Vaclavikova E, Sykorova V, Vcelak J, Novak Z, Duskova J, et al. Somatic mutations in the RET proto-oncogene in sporadic medullary thyroid carcinomas. Mol Cell Endocrinol. 2008;284(1\u20132):21\u20137.","journal-title":"Mol Cell Endocrinol"},{"issue":"3","key":"1145_CR13","doi-asserted-by":"publisher","first-page":"514","DOI":"10.3803\/EnM.2021.1082","volume":"36","author":"M Kim","year":"2021","unstructured":"Kim M, Kim BH. Current guidelines for management of medullary thyroid carcinoma. Endocrinol Metab (Seoul). 2021;36(3):514\u201324.","journal-title":"Endocrinol Metab (Seoul)"},{"issue":"12","key":"1145_CR14","doi-asserted-by":"publisher","first-page":"4390","DOI":"10.1210\/jc.2014-2811","volume":"99","author":"ME Cabanillas","year":"2014","unstructured":"Cabanillas ME, Hu MI, Jimenez C. Medullary thyroid cancer in the era of tyrosine kinase inhibitors: to treat or not to treat\u2013and with which drug\u2013those are the questions. J Clin Endocrinol Metab. 2014;99(12):4390\u20136.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"1145_CR15","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1177\/0194599820947696","volume":"164","author":"M Jin","year":"2021","unstructured":"Jin M, Megwalu UC, Noel JE. External beam radiotherapy for medullary thyroid cancer following total or near-total thyroidectomy. Otolaryngol Head Neck Surg. 2021;164(1):97\u2013103.","journal-title":"Otolaryngol Head Neck Surg"},{"issue":"3","key":"1145_CR16","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1007\/s11060-008-9783-2","volume":"93","author":"IY Kim","year":"2009","unstructured":"Kim IY, Kondziolka D, Niranjan A, Flickinger JC, Lunsford LD. Gamma knife radiosurgery for metastatic brain tumors from thyroid cancer. J Neurooncol. 2009;93(3):355\u20139.","journal-title":"J Neurooncol"},{"issue":"2","key":"1145_CR17","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1002\/cncr.11488","volume":"98","author":"RR McWilliams","year":"2003","unstructured":"McWilliams RR, Giannini C, Hay ID, Atkinson JL, Stafford SL, Buckner JC. Management of brain metastases from thyroid carcinoma: a study of 16 pathologically confirmed cases over 25 years. Cancer. 2003;98(2):356\u201362.","journal-title":"Cancer"},{"issue":"8","key":"1145_CR18","doi-asserted-by":"publisher","first-page":"2296","DOI":"10.1210\/jc.2010-1996","volume":"96","author":"JA Wexler","year":"2011","unstructured":"Wexler JA. Approach to the thyroid cancer patient with bone metastases. J Clin Endocrinol Metab. 2011;96(8):2296\u2013307.","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"1145_CR19","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1089\/thy.2013.0634","volume":"24","author":"YS Kushchayeva","year":"2014","unstructured":"Kushchayeva YS, Kushchayev SV, Wexler JA, Carroll NM, Preul MC, Teytelboym OM, et al. Current treatment modalities for spinal metastases secondary to thyroid carcinoma. Thyroid. 2014;24(10):1443\u201355.","journal-title":"Thyroid"},{"issue":"12","key":"1145_CR20","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1054\/bjoc.2001.1832","volume":"84","author":"G Vitale","year":"2001","unstructured":"Vitale G, Fonderico F, Martignetti A, Caraglia M, Ciccarelli A, Nuzzo V, et al. Pamidronate improves the quality of life and induces clinical remission of bone metastases in patients with thyroid cancer. Br J Cancer. 2001;84(12):1586\u201390.","journal-title":"Br J Cancer"},{"issue":"9","key":"1145_CR21","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1056\/NEJMoa2005651","volume":"383","author":"LJ Wirth","year":"2020","unstructured":"\u2022\u2022 Wirth LJ, Sherman E, Robinson B, Solomon B, Kang H, Lorch J, et al. Efficacy of selpercatinib in. N Engl J Med. 2020;383(9):825\u201335. This paper is about the first trial using selpercatinib in MTC.","journal-title":"N Engl J Med"},{"issue":"8","key":"1145_CR22","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/S2213-8587(21)00120-0","volume":"9","author":"V Subbiah","year":"2021","unstructured":"\u2022\u2022 Subbiah V, Hu MI, Wirth LJ, Schuler M, Mansfield AS, Curigliano G, et al. Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1\/2 study. Lancet Diabetes Endocrinol. 2021;9(8):491\u2013501. This paper is about the first trial using pralsetinib in MTC.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"1145_CR23","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1200\/JCO.2011.35.5040","volume":"30","author":"SA Wells","year":"2012","unstructured":"Wells SA, Robinson BG, Gagel RF, Dralle H, Fagin JA, Santoro M, et al. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J Clin Oncol. 2012;30(2):134\u201341.","journal-title":"J Clin Oncol"},{"issue":"11","key":"1145_CR24","doi-asserted-by":"publisher","first-page":"2813","DOI":"10.1093\/annonc\/mdx479","volume":"28","author":"M Schlumberger","year":"2017","unstructured":"Schlumberger M, Elisei R, M\u00fcller S, Sch\u00f6ffski P, Brose M, Shah M, et al. Overall survival analysis of EXAM, a phase III trial of cabozantinib in patients with radiographically progressive medullary thyroid carcinoma. Ann Oncol. 2017;28(11):2813\u20139.","journal-title":"Ann Oncol"},{"issue":"13","key":"1145_CR25","doi-asserted-by":"publisher","first-page":"3567","DOI":"10.1158\/1078-0432.CCR-20-2950","volume":"27","author":"D Li","year":"2021","unstructured":"Li D, Chi Y, Chen X, Ge M, Zhang Y, Guo Z, et al. Anlotinib in locally advanced or metastatic medullary thyroid carcinoma: a randomized, double-blind phase IIB trial. Clin Cancer Res. 2021;27(13):3567\u201375.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"1145_CR26","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1530\/EJE-17-0243","volume":"177","author":"J Capdevila","year":"2017","unstructured":"Capdevila J, Trigo JM, Aller J, Manzano JL, Adri\u00e1n SG, Llopis CZ, et al. Axitinib treatment in advanced RAI-resistant differentiated thyroid cancer (DTC) and refractory medullary thyroid cancer (MTC). Eur J Endocrinol. 2017;177(4):309\u201317.","journal-title":"Eur J Endocrinol"},{"issue":"17","key":"1145_CR27","doi-asserted-by":"publisher","first-page":"2694","DOI":"10.1002\/cncr.28766","volume":"120","author":"LD Locati","year":"2014","unstructured":"Locati LD, Licitra L, Agate L, Ou SH, Boucher A, Jarzab B, et al. Treatment of advanced thyroid cancer with axitinib: phase 2 study with pharmacokinetic\/pharmacodynamic and quality-of-life assessments. Cancer. 2014;120(17):2694\u2013703.","journal-title":"Cancer"},{"issue":"1","key":"1145_CR28","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1158\/1078-0432.CCR-15-1127","volume":"22","author":"M Schlumberger","year":"2016","unstructured":"Schlumberger M, Jarzab B, Cabanillas ME, Robinson B, Pacini F, Ball DW, et al. A phase II trial of the multitargeted tyrosine kinase inhibitor lenvatinib (E7080) in advanced medullary thyroid cancer. Clin Cancer Res. 2016;22(1):44\u201353.","journal-title":"Clin Cancer Res"},{"issue":"7","key":"1145_CR29","doi-asserted-by":"publisher","first-page":"717","DOI":"10.2217\/fon-2018-0557","volume":"15","author":"S Takahashi","year":"2019","unstructured":"Takahashi S, Kiyota N, Yamazaki T, Chayahara N, Nakano K, Inagaki L, et al. A Phase II study of the safety and efficacy of lenvatinib in patients with advanced thyroid cancer. Future Oncol. 2019;15(7):717\u201326.","journal-title":"Future Oncol"},{"issue":"14","key":"1145_CR30","doi-asserted-by":"publisher","first-page":"2323","DOI":"10.1200\/JCO.2009.25.0068","volume":"28","author":"ET Lam","year":"2010","unstructured":"Lam ET, Ringel MD, Kloos RT, Prior TW, Knopp MV, Liang J, et al. Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer. J Clin Oncol. 2010;28(14):2323\u201330.","journal-title":"J Clin Oncol"},{"issue":"21","key":"1145_CR31","doi-asserted-by":"publisher","first-page":"5260","DOI":"10.1158\/1078-0432.CCR-10-0994","volume":"16","author":"LL Carr","year":"2010","unstructured":"Carr LL, Mankoff DA, Goulart BH, Eaton KD, Capell PT, Kell EM, et al. Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation. Clin Cancer Res. 2010;16(21):5260\u20138.","journal-title":"Clin Cancer Res"},{"key":"1145_CR32","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.ejca.2017.01.029","volume":"76","author":"A Ravaud","year":"2017","unstructured":"Ravaud A, de la Fouchardi\u00e8re C, Caron P, Doussau A, Do Cao C, Asselineau J, et al. A multicenter phase II study of sunitinib in patients with locally advanced or metastatic differentiated, anaplastic or medullary thyroid carcinomas: mature data from the THYSU study. Eur J Cancer. 2017;76:110\u20137.","journal-title":"Eur J Cancer"},{"issue":"5","key":"1145_CR33","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1210\/jc.2013-3713","volume":"99","author":"KC Bible","year":"2014","unstructured":"Bible KC, Suman VJ, Molina JR, Smallridge RC, Maples WJ, Menefee ME, et al. A multicenter phase 2 trial of pazopanib in metastatic and progressive medullary thyroid carcinoma: MC057H. J Clin Endocrinol Metab. 2014;99(5):1687\u201393.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"1145_CR34","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1634\/theoncologist.2018-0452","volume":"24","author":"J Del Rivero","year":"2019","unstructured":"Del Rivero J, Edgerly M, Ward J, Madan RA, Balasubramaniam S, Fojo T, et al. Phase I\/II trial of vandetanib and bortezomib in adults with locally advanced or metastatic medullary thyroid cancer. Oncologist. 2019;24(1):16-e4.","journal-title":"Oncologist"},{"issue":"22 Pt 1","key":"1145_CR35","doi-asserted-by":"publisher","first-page":"6696","DOI":"10.1158\/1078-0432.CCR-07-0935","volume":"13","author":"F Iten","year":"2007","unstructured":"Iten F, M\u00fcller B, Schindler C, Rochlitz C, Oertli D, M\u00e4cke HR, et al. Response to [90Yttrium-DOTA]-TOC treatment is associated with long-term survival benefit in metastasized medullary thyroid cancer: a phase II clinical trial. Clin Cancer Res. 2007;13(22 Pt 1):6696\u2013702.","journal-title":"Clin Cancer Res"},{"issue":"28","key":"1145_CR36","doi-asserted-by":"publisher","first-page":"3143","DOI":"10.2217\/fon-2022-0657","volume":"18","author":"LJ Wirth","year":"2022","unstructured":"\u2022\u2022 Wirth LJ, Brose MS, Elisei R, Capdevila J, Hoff AO, Hu MI, et al. LIBRETTO-531: a phase III study of selpercatinib in multikinase inhibitor-na\u00efve. Future Oncol. 2022;18(28):3143\u201350. In this trial, selpercatinib will be compared to cabozantinib and vandetanib.","journal-title":"Future Oncol"},{"issue":"5","key":"1145_CR37","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1200\/JCO.2009.23.6604","volume":"28","author":"SA Wells","year":"2010","unstructured":"Wells SA, Gosnell JE, Gagel RF, Moley J, Pfister D, Sosa JA, et al. Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Oncol. 2010;28(5):767\u201372.","journal-title":"J Clin Oncol"},{"issue":"24","key":"1145_CR38","doi-asserted-by":"publisher","first-page":"2773","DOI":"10.1200\/JCO.19.02790","volume":"38","author":"MC Kreissl","year":"2020","unstructured":"Kreissl MC, Bastholt L, Elisei R, Haddad R, Hauch O, Jarz\u0105b B, et al. Efficacy and safety of vandetanib in progressive and symptomatic medullary thyroid cancer: post hoc analysis from the ZETA Trial. J Clin Oncol. 2020;38(24):2773\u201381.","journal-title":"J Clin Oncol"},{"issue":"24","key":"1145_CR39","doi-asserted-by":"publisher","first-page":"3856","DOI":"10.1002\/cncr.30252","volume":"122","author":"SI Sherman","year":"2016","unstructured":"Sherman SI, Clary DO, Elisei R, Schlumberger MJ, Cohen EE, Sch\u00f6ffski P, et al. Correlative analyses of RET and RAS mutations in a phase 3 trial of cabozantinib in patients with progressive, metastatic medullary thyroid cancer. Cancer. 2016;122(24):3856\u201364.","journal-title":"Cancer"},{"issue":"11","key":"1145_CR40","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1007\/s12325-013-0069-5","volume":"30","author":"E Grande","year":"2013","unstructured":"Grande E, Kreissl MC, Filetti S, Newbold K, Reinisch W, Robert C, et al. Vandetanib in advanced medullary thyroid cancer: review of adverse event management strategies. Adv Ther. 2013;30(11):945\u201366.","journal-title":"Adv Ther"},{"key":"1145_CR41","doi-asserted-by":"crossref","unstructured":"Hu M, Subbiah V, Wirth L, Schuler M, Mansfield A, Brose M, et al. Results from the registrational phase I\/II ARROW trial of pralsetinib (BLU-667) in patients (pts) with advanced RET mutation-positive medullary thyroid cancer (RET+ MTC). Ann Oncol. 2020;31.","DOI":"10.1016\/j.annonc.2020.08.1401"},{"issue":"22","key":"1145_CR42","doi-asserted-by":"publisher","first-page":"7061","DOI":"10.1158\/1078-0432.CCR-09-1241","volume":"15","author":"DS Hong","year":"2009","unstructured":"Hong DS, Sebti SM, Newman RA, Blaskovich MA, Ye L, Gagel RF, et al. Phase I trial of a combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in advanced malignancies. Clin Cancer Res. 2009;15(22):7061\u20138.","journal-title":"Clin Cancer Res"},{"issue":"8","key":"1145_CR43","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1093\/oxfordjournals.annonc.a058984","volume":"5","author":"F Orlandi","year":"1994","unstructured":"Orlandi F, Caraci P, Berruti A, Puligheddu B, Pivano G, Dogliotti L, et al. Chemotherapy with dacarbazine and 5-fluorouracil in advanced medullary thyroid cancer. Ann Oncol. 1994;5(8):763\u20135.","journal-title":"Ann Oncol"},{"issue":"10","key":"1145_CR44","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1016\/S1470-2045(20)30445-9","volume":"21","author":"A Marabelle","year":"2020","unstructured":"Marabelle A, Fakih M, Lopez J, Shah M, Shapira-Frommer R, Nakagawa K, et al. Association of tumor mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol. 2020;21(10):1353\u201365.","journal-title":"Lancet Oncol"},{"issue":"11","key":"1145_CR45","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1200\/JCO.2005.04.4917","volume":"24","author":"JF Chatal","year":"2006","unstructured":"Chatal JF, Campion L, Kraeber-Bod\u00e9r\u00e9 F, Bardet S, Vuillez JP, Charbonnel B, et al. Survival improvement in patients with medullary thyroid carcinoma who undergo pretargeted anti-carcinoembryonic-antigen radioimmunotherapy: a collaborative study with the French Endocrine Tumor Group. J Clin Oncol. 2006;24(11):1705\u201311.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1145_CR46","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1210\/clinem\/dgaa701","volume":"106","author":"X Shi","year":"2021","unstructured":"\u2022 Shi X, Li CW, Tan LC, Wen SS, Liao T, Zhang Y, et al. Immune co-inhibitory receptors PD-1, CTLA-4, TIM-3, LAG-3, and TIGIT in medullary thyroid cancers: a large cohort study. J Clin Endocrinol Metab. 2021;106(1):120\u201332. This is an interesting analysis on the expression of immune receptors in MTC.","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"1145_CR47","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.ejso.2018.10.060","volume":"45","author":"Y Bi","year":"2019","unstructured":"Bi Y, Ren X, Bai X, Meng Y, Luo Y, Cao J, Zhang Y, Liang Z. PD-1\/PD-L1 expressions in medullary thyroid carcinoma: clinicopathologic and prognostic analysis of Chinese population. Eur J Surg Oncol. 2019;45(3):353\u20138. https:\/\/doi.org\/10.1016\/j.ejso.2018.10.060.","journal-title":"Eur J Surg Oncol"},{"issue":"9","key":"1145_CR48","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1089\/thy.2019.0604","volume":"30","author":"N Pozdeyev","year":"2020","unstructured":"Pozdeyev N, Erickson TA, Zhang L, Ellison K, Rivard CJ, Sams S, et al. Comprehensive immune profiling of medullary thyroid cancer. Thyroid. 2020;30(9):1263\u201379.","journal-title":"Thyroid"},{"issue":"6","key":"1145_CR49","doi-asserted-by":"publisher","first-page":"L35","DOI":"10.1530\/ERC-17-0104","volume":"24","author":"M Bongiovanni","year":"2017","unstructured":"Bongiovanni M, Rebecchini C, Saglietti C, Bulliard JL, Marino L, de Leval L, et al. Very low expression of PD-L1 in medullary thyroid carcinoma. Endocr Relat Cancer. 2017;24(6):L35\u20138.","journal-title":"Endocr Relat Cancer"},{"issue":"15_suppl","key":"1145_CR50","doi-asserted-by":"publisher","first-page":"6513","DOI":"10.1200\/JCO.2020.38.15_suppl.6513","volume":"38","author":"JH Lorch","year":"2020","unstructured":"Lorch JH, Barletta JA, Nehs M, Uppaluri R, Alexander EK, Haddad RI, et al. A phase II study of nivolumab (N) plus ipilimumab (I) in radioidine refractory differentiated thyroid cancer (RAIR DTC) with exploratory cohorts in anaplastic (ATC) and medullary thyroid cancer (MTC). J Clin Oncol. 2020;38(15_suppl):6513\u20133. https:\/\/doi.org\/10.1200\/JCO.2020.38.15_suppl.6513.","journal-title":"J Clin Oncol"},{"issue":"10","key":"1145_CR51","doi-asserted-by":"publisher","first-page":"4965","DOI":"10.1210\/jcem.86.10.7949","volume":"86","author":"M Schott","year":"2001","unstructured":"Schott M, Seissler J, Lettmann M, Fouxon V, Scherbaum WA, Feldkamp J. Immunotherapy for medullary thyroid carcinoma by dendritic cell vaccination. J Clin Endocrinol Metab. 2001;86(10):4965\u20139.","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"1145_CR52","doi-asserted-by":"publisher","first-page":"2944","DOI":"10.1158\/1078-0432.CCR-03-0698","volume":"10","author":"A Stift","year":"2004","unstructured":"Stift A, Sachet M, Yagubian R, Bittermann C, Dubsky P, Brostjan C, et al. Dendritic cell vaccination in medullary thyroid carcinoma. Clin Cancer Res. 2004;10(9):2944\u201353.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"1145_CR53","first-page":"247","volume":"47","author":"F Kraeber-Bod\u00e9r\u00e9","year":"2006","unstructured":"Kraeber-Bod\u00e9r\u00e9 F, Rousseau C, Bodet-Milin C, Ferrer L, Faivre-Chauvet A, Campion L, et al. Targeting, toxicity, and efficacy of 2-step, pretargeted radioimmunotherapy using a chimeric bispecific antibody and 131I-labeled bivalent hapten in a phase I optimization clinical trial. J Nucl Med. 2006;47(2):247\u201355.","journal-title":"J Nucl Med"},{"issue":"1","key":"1145_CR54","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1038\/s41421-022-00479-y","volume":"8","author":"X Shi","year":"2022","unstructured":"\u2022 Shi X, Sun Y, Shen C, Zhang Y, Shi R, Zhang F, et al. Integrated proteogenomic characterization of medullary thyroid carcinoma. Cell Discov. 2022;8(1):120. This is an interesting review of proteogenomic in MTC.","journal-title":"Cell Discov"},{"key":"1145_CR55","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/bs.acr.2023.01.001","volume":"158","author":"A Kumar","year":"2023","unstructured":"\u2022\u2022 Kumar A, Emdad L, Fisher PB, Das SK. Targeting epigenetic regulation for cancer therapy using small molecule inhibitors. Adv Cancer Res. 2023;158:73\u2013161. This article analyzes new possible targets for future MTC treatment.","journal-title":"Adv Cancer Res"},{"issue":"5","key":"1145_CR56","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1097\/PPO.0000000000000278","volume":"23","author":"EM Da Costa","year":"2017","unstructured":"Da Costa EM, McInnes G, Beaudry A, Raynal NJ. DNA methylation-targeted drugs. Cancer J. 2017;23(5):270\u20136.","journal-title":"Cancer J"}],"container-title":["Current Treatment Options in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-023-01145-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11864-023-01145-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-023-01145-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,10]],"date-time":"2024-01-10T07:19:42Z","timestamp":1704871182000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11864-023-01145-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,18]]},"references-count":56,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["1145"],"URL":"https:\/\/doi.org\/10.1007\/s11864-023-01145-5","relation":{},"ISSN":["1527-2729","1534-6277"],"issn-type":[{"value":"1527-2729","type":"print"},{"value":"1534-6277","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,18]]},"assertion":[{"value":"24 October 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}